Literature DB >> 27431984

Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Peter J Chockley1, Venkateshwar G Keshamouni2.   

Abstract

Microenvironments that tumor cells encounter are different during the stages of cancer progression-primary tumor, metastasis, and at the metastatic site. This suggests potential differences in immune surveillance of primary tumor and metastasis. Epithelial-mesenchymal transition (EMT) is a key reversible process in which cancer cells transition into highly motile and invasive cells for dissemination. Only a tiny proportion successfully metastasize, supporting the notion of metastasis-specific immune surveillance. EMT involves extensive molecular reprogramming of cells conferring many clinically relevant features to cancer cells and affects tumor cell interactions within the tumor microenvironment. We review the impact of tumor immune infiltrates on tumor cell EMT and the consequences of EMT in shaping the immune microenvironment of tumors. The usefulness of EMT as a model to investigate metastasis-specific immune surveillance mechanisms are also explored. Finally, we discuss potential implications of EMT for tumor immunogenicity, as well as current immunotherapies and future strategies.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27431984      PMCID: PMC4955875          DOI: 10.4049/jimmunol.1600458

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

2.  Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.

Authors:  Intissar Akalay; Bassam Janji; Meriem Hasmim; Muhammad Zaeem Noman; Fabrice André; Patricia De Cremoux; Philippe Bertheau; Cécile Badoual; Philippe Vielh; Annette K Larsen; Michèle Sabbah; Tuan Zea Tan; Joan Herr Keira; Nicole Tsang Ying Hung; Jean Paul Thiery; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Cancer Res       Date:  2013-02-22       Impact factor: 12.701

3.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Authors:  Min Soon Cho; Rajesha Rupaimoole; Hyun-Jin Choi; Kyunghee Noh; Jichao Chen; Qianghua Hu; Anil K Sood; Vahid Afshar-Kharghan
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

4.  Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines.

Authors:  Niels Halama; Monika Braun; Christoph Kahlert; Anna Spille; Christian Quack; Nuh Rahbari; Moritz Koch; Jürgen Weitz; Matthias Kloor; Inka Zoernig; Peter Schirmacher; Karsten Brand; Niels Grabe; Christine S Falk
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

5.  Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.

Authors:  Linda Wang; Esther W Y Chang; Siew Cheng Wong; Siew-Min Ong; Debra Q Y Chong; Khoon Lin Ling
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

Review 6.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

Review 7.  Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Authors:  Dingcheng Gao; Linda T Vahdat; Stephen Wong; Jenny C Chang; Vivek Mittal
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

8.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

Review 9.  The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

Authors:  Clare Y Slaney; Jai Rautela; Belinda S Parker
Journal:  Cancer Res       Date:  2013-09-23       Impact factor: 12.701

10.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Authors:  Bin Zhang; Zhijun Wang; Liangliang Wu; Meng Zhang; Wei Li; Jianhua Ding; Jun Zhu; Huafeng Wei; Ke Zhao
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

View more
  31 in total

Review 1.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

Review 2.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

3.  Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.

Authors:  Peter J Chockley; Jun Chen; Guoan Chen; David G Beer; Theodore J Standiford; Venkateshwar G Keshamouni
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

4.  The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3+CD8+ tumor infiltrating lymphocyte subpopulations.

Authors:  Stefan Koeck; Johan Kern; Marit Zwierzina; Gabriele Gamerith; Edith Lorenz; Sieghart Sopper; Heinz Zwierzina; Arno Amann
Journal:  Oncoimmunology       Date:  2017-05-08       Impact factor: 8.110

Review 5.  Cellular Plasticity in Cancer.

Authors:  Salina Yuan; Robert J Norgard; Ben Z Stanger
Journal:  Cancer Discov       Date:  2019-04-16       Impact factor: 39.397

6.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.

Authors:  Robert M Samstein; Chirag Krishna; Xiaoxiao Ma; Xin Pei; Ken-Wing Lee; Vladimir Makarov; Fengshen Kuo; Jonathan Chung; Raghvendra M Srivastava; Tanaya A Purohit; Douglas R Hoen; Rajarsi Mandal; Jeremy Setton; Wei Wu; Rachna Shah; Besnik Qeriqi; Qing Chang; Sviatoslav Kendall; Lior Braunstein; Britta Weigelt; Pedro Blecua Carrillo Albornoz; Luc G T Morris; Diana L Mandelker; Jorge S Reis-Filho; Elisa de Stanchina; Simon N Powell; Timothy A Chan; Nadeem Riaz
Journal:  Nat Cancer       Date:  2020-11-16

Review 7.  Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.

Authors:  Anastasios Gkountakos; Pietro Delfino; Rita T Lawlor; Aldo Scarpa; Vincenzo Corbo; Emilio Bria
Journal:  Ther Adv Med Oncol       Date:  2021-05-25       Impact factor: 8.168

Review 8.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

Review 9.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

Review 10.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.